We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Antibody Cocktail Reduces Incidence of Severe COVID-19, Death
AstraZeneca’s Antibody Cocktail Reduces Incidence of Severe COVID-19, Death
AstraZeneca announced that its COVID-19 long-acting antibody (LAAB) combination, AZD7442, significantly reduced severity of COVID-19 as well as death in a phase 3 trial.